It has been reported that oncogenic KRAS mutations, and subsequent activation of the downstream effectors, such as Erk, Akt, and MEK, can result in the modulation of pancreatic cancer (Kamerkar et al., 2017). This evidence concerns the gene KRAS and familial pancreatic carcinoma.